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Non-oliguric hyperkalaemia (NOHK) in 
neonates is defined as a plasma potassium 
level > 6.5 mmol/L in the presence of urine 
output ≥ 1 mL/kg/h during the first 72 
hours of life. It is characterized by a rapid 
rise of serum potassium to excessively high 
values, a high risk of cardiac arrhythmias 
and no occurrence after 72 hours of birth. 
NOHK commonly occurs in premature 
neonates, especially in those with a ges-
tational age <28 weeks, with only a few 
reports of this entity in moderate or late 
preterm neonates. The effectiveness and 
safety of different treatments for NOHK 
is uncertain and currently there is no firm 
treatment recommendation. We describe 
the case of a moderately premature neo-
nate (32+ 2 weeks gestation), with severe 
neonatal respiratory distress syndrome, 
who developed NOHK that was treated 
with inhaled salbutamol. When salbuta-
mol is used for the treatment of NOHK, an 
initial paradoxical rise in potassium levels 
should always be taken into account to 
avoid cardiac arrhythmias.
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INTRODUCTION
Non-oliguric hyperkalaemia (NOHK) is a 
common and serious complication in pre-
mature neonates, especially in those with 
very low birth weight (<1500g) and/or 
very preterm (≤28 weeks gestational age). 
(1,2) The reported incidence of NOHK is 
11% to 52%. (3-5) With increased survival 
of premature neonates, NOHK is becom-
ing more common. (5) 
Reversible hyperkalaemia in premature ne-
onates was first reported in 1959 by Usher. 
(6) Characteristics of NOHK as we know it 
today were described by Perkkiö and Räihä 
(7) in 1977. NOHK is defined as a serum 
potassium ≥ 6.5mmol/L during the first 72 
hours of life in a non-haemolysed arterial 
or venous blood sample in the presence of 
urine output ≥ 1 mL/kg/h. (2) It is char-
acterized by a rapid rise in serum potas-
sium to excessively high values after birth 
in premature neonates, a high risk of car-
diac arrhythmias and no occurrence after 
72 hours of birth. The pathophysiology of 
NOHK is not completely understood. Cur-
rent evidence suggests that it is mainly due 
to a shift in potassium from the intra- into 
the extracellular spaces because of imma-
ture function of the Na+/K+ ATPase in 
premature neonates. (5,8-10) More than 
80% of neonates with NOHK are extreme-
ly low birth weight (ELBW) infants with 
gestational age below 28 weeks. (4) Few 
cases have been reported in moderate to 
late preterm neonates. (1,4) The effective-
ness and safety of different treatment op-
tions for NOHK is uncertain and currently 
there is no firm treatment recommenda-
tion. (2) We describe a case of a moderately 
premature neonate (32+2 weeks gestation) 
with severe neonatal respiratory distress 
syndrome, who developed NOHK that was 
treated with inhaled salbutamol.
CASE REPORT
A premature girl was admitted to the in-
terdisciplinary neonatal and paediatric in-
tensive care unit (ICU) of the Department 
of Paediatric Surgery and Intensive Care, 
University Medical Centre Ljubljana, Slo-
venia because of respiratory distress. Due 
to incipient premature labour, the mother 
received a course of antenatal steroids 
(betamethasone) 16 days before delivery. 
The girl was delivered at 32 weeks and 2 
days gestational age at the regional mater-
nity hospital by caesarean section after mi-
nor antepartum haemorrhage because of 
placenta praevia and persistent foetal tach-
ycardia. The girl weighed 1900 g and ap-
peared vigorous, with spontaneous respi-
rations; the 1-minute and 5-minute Apgar 
scores were 8 and 9, respectively. Haemo-
globin level at birth was 126 g/L, which was 
an indicator that she suffered some blood 
loss because of placenta praevia. Shortly 
after birth she developed tachypnoea with 
shallow respirations and retractions. Fea-
tures of severe hyaline membrane disease 
were found on chest X-ray. Endotracheal 
intubation was performed and assisted 
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Figure 1. Serum potassium levels in patient 
with NOHK. Inhalations of salbutamol are 
marked   
● salbutamol inhalation
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ventilation begun. The baby developed 
bilateral pneumothoraxes, requiring chest 
drainage. Transfer to a tertiary hospital 
was arranged. Surfactant, high-frequency 
oscillator ventilation, and nitric oxide were 
administered. Due to anaemia she received 
a blood transfusion at postnatal age of 
12 hours. Her respiratory status gradu-
ally improved (15 days of invasive and 20 
days of non-invasive ventilation). Ultra-
sonography of the brain revealed grade 
1 haemorrhage into the germinal matrix 
bilaterally. Because of bronchopulmonary 
dysplasia she needed supplemental oxygen 
until postnatal age of 6 months. Her neu-
rodevelopmental status at postnatal age of 
12 months was normal. Her renal function 
was normal.
Laboratory parameters were regularly 
checked after birth (table 1). Potassium se-
rum concentrations (K+) were in the low 
normal range for the first 36 hours of life, 
despite rather low pH values (table 1, figure 
1). Urinary output was monitored closely 
and was high – early polyuria (first day: 3.5 
ml/kg/h, second day 6.3 ml/kg/h, third day 
5.6 ml/kg/h, fourth day 7.8 ml/kg/h, fifth 
day 7 ml/kg/h). There was hyperphospha-
taemia, hypocalcaemia and hypomagne-
saemia. Due to early hyperglycaemia she 
received an insulin infusion for 7 h during 
the first day of life. After discontinuation of 
the insulin infusion, glucose levels were be-
low 10 mmol/L. At 42 hours of age K+ rose 
to 5.8 mmoL/L. She was receiving only po-
tassium-free infusions. As seen in figure 1, 
a further increase in K+ occurred with the 
maximum level reached at 53 hours of age 
(7.9 mmol/L). When the K+ level reached 
7.8 mmol/L, tall peaked T waves were no-
ticed on the ECG. The baby was already 
receiving supplementation with calcium 
gluconate every 6 hours due to low levels 
of ionized calcium. Despite this, an addi-
tional dose of calcium gluconate 10% 100 
mg (1ml)/kg was administered and shortly 
thereafter the ECG normalized. When the 
K+ level reached 7.8 mmol/L, salbutamol 
was given by nebulizer (400 μg = 200 μg/
kg). The dose was repeated every 2 hours 
until the K+ level fell below 5 mmol/L, 
thereafter the dose was repeated every 
4 hours for another 12 hours. The potas-
sium level slightly increased after the first 
inhalation of salbutamol (figure 1), but 
declined rapidly thereafter and reached 
6.0 mmol/L within 6 hours following the 
first inhalation. Changes in heart rate and 
blood pressure after salbutamol inhalation 
are shown in table 2.
DISCUSSION
Even though NOHK is most common in 
ELBW infants with a gestational age < 28 
weeks (4) and there are only a few reports 
of this entity in late preterm infants, (1,4) 
our report emphasizes that NOHK can oc-
Table 1. Blood gas, electrolytes, urea, creatinine and glucose levels at different times after birth. Samples at postnatal age of 4 minutes and 























4 min 7.26 7.3 21.6 3.9 135 1.49 4.6
1h 7.08 9.8 15.0 4.2 137 1.83 4.1
3 h 7.40 5.5 19.8 4.1 136 1.2 7.2
6 h 7.05 5.9 11.3 3.9 141 1.76 1.07 2.53 0.82 4.8 74 16.7
9 h 7.17 5.9 15.8 3.9 133 1.98 1.03 3.0 0.86 4.3 84 24.1
12 h 7.31 4.5 16.3 3.9 134 0.7 23.8
15 h 7.17 5.9 15.6 3.5 143 1.48 0.8 2.93 0.51 4.3 66 11.3
24 h 7.38 5.2 20.7 3.6 140 1.72 1.08 2.85 1.1 6.1 72 8.9
33 h 7.29 7.2 25.1 4.0 138 2.0 1.12 2.63 1.1 6.1 44 9.0
36 h 7.31 5.6 20.5 4.7 136 2.23 1.02 2.77 1.0 7.3 79 5.4
42 h 7.32 5.5 20.9 5.8 138 2.18 0.95 2.77 1.0 7.3 78 5.9
48 h 7.31 6.0 22.0 6.1 142 1.82 1.1 2.79 0.9 7.9 88 9.0
52 h 7.34 5.4 21.0 7.8 140 2.0 1.1 2.95 1.0 7.8 90 10.0
53 h 7.33 5.5 20.0 7.9 139 2.1 1.4 2.85 1.1 7.5 89 9.5
54 h 7.33 5.6 20.0 7.4 138 1.2 10.5
56 h 7.34 5.7 21.0 6.9 138 1.3 9.0
58 h 7.36 5.2 20.0 6.0 139 1.1 9.5
60 h 7.39 4.9 20.1 5.6 140 2.1 1.2 2.80 1.0 8.8 75 6.8
64 h 7.41 5.6 20.0 5.2 143 1.8 1.0 2.72 0.8 8.7 75 4.2
68 h 7.40 5.9 22.0 4.8 143 2.1 1.1 2.74 0.9 8.3 72 5.6
72 h 7.39 5.8 24.0 4.6 144 2.1 1.1 2.81 0.8 8.2 75 8.0
80 h 7.42 6.0 24.0 4.5 143 2.4 1.2 3.24 0.9 8.0 70 9.7
88 h 7.38 6.1 22.0 4.3 140 2.5 1.3 2.7 0.8 8.0 65 8.5
96 h 7.37 6.0 23.0 4.2 142 2.2 1.2 2.0 0.8 7.5 60 5.3
Ca++, calcium ion; creat., creatinine; glu., glucose; HCO3, hydrogen carbonate; iCa, ionized calcium; K+, potassium ion; Mg++, mag-
nesium ion; P, phosphate; PCO2, partial pressure of carbon dioxide.
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cur in more mature preterm infants. The 
characteristic feature of NOHK is a rapid 
rise in serum K+ to high values during the 
first 72 h of life. (5) In our infant, as seen 
in Figure 1, K+ increased steeply between 
42 and 52 hours of age. Low to normal K+ 
levels during the first 36 h of life in our re-
port underscores the importance of regu-
lar electrolyte checks in preterm infants 
during the first days of life. 
Antenatal steroid therapy may reduce hy-
perkalaemia. (8,11) In our report NOHK 
developed despite antenatal steroids. How-
ever, the peak K+ level might have been 
higher in the absence of antenatal steroids. 
(8) Current evidence suggests NOHK is 
mainly due to a shift of K+ from the in-
tra- into the extracellular space because of 
immature function of the Na+/K+ ATPase 
in premature neonates. (5,8-10) Antena-
tal steroids upregulate Na+/K+ ATPase 
activity. (5,8-10) Impairment of the Na+/
K+ ATPase during hypoxia, acidosis and 
hypoglycaemia explain the association of 
NOHK with foetal distress, early meta-
bolic acidosis, and early hyperglycaemia. 
(3,4,12) All of these features were present 
in our patient.
Apart from the loss of K+ into the extra-
cellular space, other plausible mechanisms 
for hyperkalaemia are increased K+ intake 
and decreased K+ excretion, but these are 
not causes of NOHK (2) and were ruled 
out in the case described. Our patient 
was infused potassium-free solutions. The 
theoretical possibility of increased potas-
sium load by red cell transfusion is very 
unlikely as transfusion was administered 
at 12 h of life and transfusion as a cause of 
NOHK has been ruled out by several au-
thors. (10,13-15) NOHK is not associated 
with decreased diuresis, reflecting dimin-
ished glomerular filtration and polyuria, 
as was seen in our case. (3,13,16) NOHK 
has been shown to be unrelated to leak-
age of K+ from cell disruption associated 
with bruising, intracranial haemorrhage, 
or haemolysis. (5,13,17)
NOHK is associated with a high risk of 
cardiac arrhythmias, (5,8) especially with 
K+ levels higher than 7 mmol/l. (5,6) Tall 
peaked T waves developed in our patient 
when the K+ level reached 7.8 mmol/L; 
the ECG quickly normalized after calcium 
administration. As mortality related to 
NOHK is reported to be 12% and in the 
report by Sychlowy et al. only one in seven 
infants with cardiac arrhythmias second-
ary to NOHK survived, (18) NOHK rep-
resents an emergency situation requiring 
prompt therapy. The high incidence of 
cardiac arrhythmias is probably related to 
the common occurrence of hypocalcae-
mia in preterm infants, with lowest values 
of Ca++ occurring at a time when NOHK 
sets in. (14,19) 
Several treatment approaches are used in 
NOHK, all adapted from the treatment of 
hyperkalaemia due to renal failure in in-
fants. However, hyperkalaemia in NOHK 
has a different pathogenesis. In view of 
the limited information from small stud-
ies, the effectiveness and safety of different 
treatment options for NOHK is uncertain 
and currently no treatment guidelines 
can be recommended. (2) Administra-
tion of intravenous calcium is supported 
when ECG changes occur to counteract 
the arrhythmogenicity of hyperkalaemia. 
(5,14,19) 
The effect of salbutamol on transmem-
brane K+  flux has been studied in neo-
natal red blood cells under hyperkalaemic 
conditions and resulted in a 50% increase 
in net transmembrane K+ flux. No such 
increase occurred in adult red blood cells. 
(20) Salbutamol inhalation or infusion 
is effective in lowering serum potassium 
concentrations in adults and children be-
yond the neonatal period. (5) Salbutamol 
treatment has only anecdotally been re-
ported for the treatment of hyperkalaemia 
in neonates, usually as an infusion. (21) 
Singh et al. reported on the efficacy and 
safety of inhaled albuterol for the treat-
ment of NOHK in premature neonates. 
(22) Our report is one of only a few that 
describes salbutamol inhalation for the 
treatment of NOHK and underscores the 
effectiveness of this treatment approach. 
In our case, salbutamol was given by nebu-
lization every 2 hours until the K+ level 
fell below 5 mmol/L, thereafter the dose 
was repeated every 4 hours for another 12 
hours. The K+ decreased from a peak level 
to 6 mmol/l over the course of 6 h. There 
are some safety concerns about salbutamol 
use in hyperkalaemia. (5) Firstly, salbuta-
mol increases heart rate and blood pres-
sure by stimulating β1 adrenoceptors. In 
our case (table 2), the mean arterial pres-
sure and heart rate increased significantly 
after salbutamol inhalation, but this adr-
energic stimulation was not excessive and 
Table 2. Difference in blood pressure and heart rate before and after salbutamol inhalation
Blood pressure (mmHg) MAP (mmHg) Heart rate (beats/min)














































































Median 50 55 137 146
Q1 48 51 135 142
Q3 52 58 146 155
IQR 4 7 11 13
p-value 0,0653 0,0028
IQR, interquartile range; MAP, mean arterial blood pressure; Q1, first quartile; Q3, third quartile.
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clinically relevant.  Secondly, a slight initial 
rise in K+ (≈0.1mmol/L) has been report-
ed between 1 and 3 minutes after salbuta-
mol administration, before the hypokalae-
mic effect takes place. (23) We noticed the 
same slight transient increase in K+  (0.1 
mmol/L) after the first dose of salbutamol 
followed by a significant decrease in K+. 
The early paradoxical increase in K+ may 
be the result of K+ release from skeletal 
muscle after β2 adrenoceptor stimulation. 
Whether this increase in K+ in already hy-
perkalaemic infants may provoke cardiac 
arrhythmias, especially as salbutamol also 
facilitates cardiac excitability through β1 
adrenoceptor stimulation, is unknown.
To conclude, this report underscores the 
need to recognize the possibility of NOHK 
in moderately and late preterm infants as 
well as in very preterm infants. Even in the 
face of low or normal K+ during the first 
24 h of life, K+ should be checked every 
six hours during the first days of life as K+ 
can quickly rise and lead to rhythm dis-
turbances. As seen in our case, salbutamol 
inhalation can effectively and rapidly lower 
K+ in NOHK, but the paradoxical increase 
in K+ during the first minutes following 
administration needs to be taken into ac-
count. It seems reasonable to administer 
calcium first to stabilize the myocardium 
and then commence salbutamol inhala-
tion. With no absolute treatment recom-
mendation, and in view of the limited 
information from small studies, the effec-
tiveness of potentially beneficial interven-
tions should be tested in further studies. 
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